Inhibiting the HIF2 protein was found to promote repair processes in a mouse model of lung injury, and may be a strategy for ...
With idiopathic pulmonary fibrosis, columnist Sam Kirton continues to learn to be prepared for emergencies, such as the Los Angeles fires.
Fatty acid synthase, the enzyme responsible for fatty acid production in cells, may be a therapeutic target for IPF, a mouse ...
As columnist Charlene Marshall looks ahead to 2025, she shares some of her New Year's wishes for fellow pulmonary fibrosis patients.
Do you make resolutions for the new year? A revealing joke on the subject has been around for years. In it, an entrepreneur opens and stocks a gym on New Year’s Day to support those who’ve made ...
Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.
The investigational therapy LYT-100 (deupirfenidone) significantly slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF), outperforming the standard of care therapy Esbriet.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback